Affymetrix Unveils Plans to Double Plant and Animal Genome Microarray Offering
January 17 2005 - 8:30AM
PR Newswire (US)
Affymetrix Unveils Plans to Double Plant and Animal Genome
Microarray Offering Current Plant and Animal Genome Arrays to Be
Featured in Over Twenty Posters and Presentations at the Plant and
Animal Genome XIII Conference SANTA CLARA, Calif., Jan. 17
/PRNewswire-FirstCall/ -- Today, Affymetrix, Inc. (NASDAQ:AFFX)
announced plans to make eight new GeneChip(R) plant and animal
genome arrays available in 2005 as part of its Consortia Program,
including canine, Rhesus macaque, Medicago trancatula (legume),
Brassica, tomato, citrus, poplar and sugar cane. More than 20
research presentations at this week's Plant and Animal Genome
Conference XIII in San Diego, Calif. feature Affymetrix arrays
launched in 2004 under the Consortia Program. Some of the studies
being presented include: -- Dr. John Cushman who monitored
environmental stresses in the wine grape -- Dr. Matias Kirst who
studied SNP effects in expression analysis of diverse species using
an early prototype of the maize array -- Dr. Brett Tyler who
studied transcriptional profiling of Phytophthora sojae infection
of the soybean plant The Affymetrix GeneChip Consortia Program is a
collaborative initiative that enables the plant and animal research
communities to consolidate their sequence data on the Affymetrix
industry-standard GeneChip brand platform. In 2004 Affymetrix
worked closely with global research communities to launch eight
plant and animal genome arrays: Vitis vinifera (grape), soybean,
wheat, rice, maize, bovine, chicken, and porcine. "By underwriting
the design fees required to produce these new arrays, Affymetrix is
putting GeneChip technology within reach of virtually any research
community," said Lianne McLean, Director, Gene Expression Marketing
at Affymetrix. "We had great success with this program last year.
By providing the plant and animal community groups with a single,
standardized platform for gene expression research, they can easily
compare results, build reliable databases and move science forward
more quickly." Affymetrix Consortia Program arrays are developed
using the same reliable design and manufacturing process that have
made Affymetrix the industry-standard technology for gene
expression analysis. Over the past ten years more than 3,000 papers
have been published using GeneChip technology. For more
information, please visit http://www.affymetrix.com/. About
Affymetrix: Affymetrix scientists invented the world's first
high-density microarray in 1989 and began selling the first
commercial microarray in 1994. Since then, Affymetrix GeneChip(R)
technology has become the industry standard in molecular biology
research. Affymetrix technology is used by the world's top
pharmaceutical, diagnostic and biotechnology companies as well as
leading academic, government and not-for-profit research
institutes. More than 1,000 systems have been installed around the
world and nearly 3,000 peer-reviewed papers have been published
using the technology. Affymetrix' patented photolithographic
manufacturing process provides the most information capacity
available today on an array, enabling researchers to use a
whole-genome approach to analyzing the relationship between
genetics and health. Affymetrix is headquartered in Santa Clara,
Calif., with manufacturing facilities in Sacramento, Calif., and
Bedford, Mass. The company maintains important sales and marketing
operations in Europe and Asia and has about 900 employees
worldwide. All statements in this press release that are not
historical are "forward-looking statements" within the meaning of
Section 21E of the Securities Exchange Act as amended, including
statements regarding Affymetrix' "expectations," "beliefs,"
"hopes," "intentions," "strategies" or the like. Such statements
are subject to risks and uncertainties that could cause actual
results to differ materially for Affymetrix from those projected,
including, but not limited to risks of the Company's ability to
achieve and sustain higher levels of revenue, higher gross margins,
reduced operating expenses, uncertainties relating to technological
approaches, manufacturing, product development (including
uncertainties Consortia Program Arrays) personnel retention,
uncertainties related to cost and pricing of Affymetrix products,
dependence on collaborative partners, uncertainties relating to
sole source suppliers, uncertainties relating to FDA and other
regulatory approvals, competition, risks relating to intellectual
property of others and the uncertainties of patent protection and
litigation. These and other risk factors are discussed in
Affymetrix' Form 10-K for the year ended December 31, 2003 and
other SEC reports, including its Quarterly Reports on Form 10-Q for
subsequent quarterly periods. Affymetrix expressly disclaims any
obligation or undertaking to release publicly any updates or
revisions to any forward-looking statements contained herein to
reflect any change in Affymetrix' expectations with regard thereto
or any change in events, conditions, or circumstances on which any
such statements are based. NOTE: Affymetrix, the Affymetrix logo,
and GeneChip are registered trademarks owned or used by Affymetrix,
Inc. DATASOURCE: Affymetrix, Inc. CONTACT: media, Wes Conard,
Associate Director, Public Relations, +1-408-731-5791, or
investors, Doug Farrell, Vice President, Investor Relations,
+1-408-731-5285, both of Affymetrix, Inc. Web site:
http://www.affymetrix.com/
Copyright
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Sep 2024 to Oct 2024
Affymetrix (NASDAQ:AFFX)
Historical Stock Chart
From Oct 2023 to Oct 2024